Show simple item record

dc.contributor.authorMilton, S
dc.contributor.authorMcIntosh, J
dc.contributor.authorMacrae, F
dc.contributor.authorChondros, P
dc.contributor.authorTrevena, L
dc.contributor.authorJenkins, M
dc.contributor.authorWalter, FM
dc.contributor.authorTaylor, N
dc.contributor.authorBoyd, L
dc.contributor.authorSaya, S
dc.contributor.authorKarnchanachari, N
dc.contributor.authorNovy, K
dc.contributor.authorForbes, C
dc.contributor.authorGutierrez, JM
dc.contributor.authorBroun, K
dc.contributor.authorWhitburn, S
dc.contributor.authorMcGill, S
dc.contributor.authorFishman, G
dc.contributor.authorMarker, J
dc.contributor.authorShub, M
dc.contributor.authorEmery, J
dc.date.accessioned2021-09-03T17:23:14Z
dc.date.available2021-06-09
dc.date.available2021-09-03T17:23:14Z
dc.date.issued2021-07-15
dc.identifier.citationMilton, S., McIntosh, J., Macrae, F. et al. An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial. Trials 22, 452 (2021). https://doi.org/10.1186/s13063-021-05365-8en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/73880
dc.description.abstractBACKGROUND: Australian guidelines recommend that all people aged 50-70 years old actively consider taking daily low-dose aspirin (100-300 mg per day) for 2.5 to 5 years to reduce their risk of colorectal cancer (CRC). Despite the change of national CRC prevention guidelines, there has been no active implementation of the guidelines into clinical practice. We aim to test the efficacy of a health consultation and decision aid, using a novel expected frequency tree (EFT) to present the benefits and harms of low dose aspirin prior to a general practice consultation with patients aged 50-70 years, on informed decision-making and uptake of aspirin. METHODS: Approximately five to seven general practices in Victoria, Australia, will be recruited to participate. Patients 50-70 years old, attending an appointment with their general practitioner (GP) for any reason, will be invited to participate in the trial. Two hundred fifty-eight eligible participants will be randomly allocated 1:1 to intervention or active control arms using a computer-generated allocation sequence stratified by general practice, sex, and mode of trial delivery (face-to-face or teletrial). There are two co-primary outcomes: informed decision-making at 1-month post randomisation, measured by the Multi-dimensional Measure of Informed Choice (MMIC), and self-reported daily use of aspirin at 6 months. Secondary outcomes include decisional conflict at 1-month and other behavioural changes to reduce CRC risk at both time points. DISCUSSION: This trial will test the efficacy of novel methods for implementing national guidelines to support informed decision-making about taking aspirin in 50-70-year-olds to reduce the risk of CRC and other chronic diseases. TRIAL REGISTRATION: The Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12620001003965 . Registered on 10 October 2020.en_US
dc.format.extent452 - ?
dc.languageeng
dc.publisherBioMed Centralen_US
dc.relation.ispartofTrials
dc.rightsCreative Commons Attribution 4.0 International License
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAspirinen_US
dc.subjectBowel canceren_US
dc.subjectCancer preventionen_US
dc.subjectChemopreventionen_US
dc.subjectColorectal canceren_US
dc.subjectDecision Aiden_US
dc.subjectGeneral practiceen_US
dc.subjectGuideline implementationen_US
dc.subjectInformed decision makingen_US
dc.subjectPreventive medicineen_US
dc.subjectPrimary careen_US
dc.subjectAgeden_US
dc.subjectAspirinen_US
dc.subjectChronic Diseaseen_US
dc.subjectColorectal Neoplasmsen_US
dc.subjectDecision Support Techniquesen_US
dc.subjectHumansen_US
dc.subjectMiddle Ageden_US
dc.subjectRandomized Controlled Trials as Topicen_US
dc.subjectVictoriaen_US
dc.titleAn RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial.en_US
dc.typeArticleen_US
dc.rights.holder© The Author(s). 2021
dc.identifier.doi10.1186/s13063-021-05365-8
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34266464en_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.publisher-urlhttps://doi.org/10.1186/s13063-021-05365-8
pubs.volume22en_US
dcterms.dateAccepted2021-06-09
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International License
Except where otherwise noted, this item's license is described as Creative Commons Attribution 4.0 International License